Coverage with evidence development; Implementation; Innovation; Radiotherapy; Real-world data; Stereotactic body radiotherapy; Oncology; Health Policy; registry; reimbursement; social security
Abstract :
[en] [en] BACKGROUND: Although stereotactic body radiotherapy (SBRT) was progressively adopted in clinical practice in Belgium, a reimbursement request in 2011 was not granted because of remaining clinical and economic uncertainty. A coverage with evidence development (CED) program on SBRT started in 2013, with the aim to assess clinical and technical patterns-of-care in Belgium and monitor survival per indication, in view of supporting inclusion in the reimbursement system.
METHODS: The Belgian National Institute for Health and Disability Insurance (NIHDI) initiated this prospective observational registry. Participating departments, using SBRT in clinical practice, signed the 'NIHDI convention'. Eligible patients had a primary tumour (PT) or oligometastatic disease (OMD). Patient, tumour, and treatment characteristics were collected through an online module of the Belgian Cancer Registry, prerequisite for financing. Five-year overall survival (5YOS) and 30- and 90-days mortality were primary outcomes, derived from vital status information.
FINDINGS: Between 10/2013 and 12/2019, 20 of the 24 accredited radiotherapy departments participated, 6 were academic. Registered cases per department ranged from 21 to 867. Of 5675 registrations analysed, the majority had good performance status and limited number of lesions. Enrolment of PTs remained stable over time, OMDs almost doubled. Peripheral lung lesions dominated in PTs as in OMDs. Other metastases were (para)spinal, 'non-standard' and hepatic. Thirty- and 90-days mortalities remained below 0.5% [95% CI 0.3%-0.8%] respectively 2.1% [95% CI 1.6%-2.7%]. 5YOS varied by indication, primary prostate patients performing best (85%, 95% CI [76%, 96%]), those with liver metastases worst (19%, 95% CI [15%, 24%]). Better OS was observed in academic departments, department size did not significantly impact survival. OMD survival was better in 2018-19.
INTERPRETATION: CED can be used to define patterns-of-care and real-life outcome of innovative radiotherapy. As the observed survival for different indications was in line with outcome in emerging literature, SBRT was included in the Belgian reimbursement system as of January 2020.
FUNDING: NIHDI financed participating departments per registered case.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Lievens, Yolande ; Radiation Oncology Department, Ghent University Hospital and Ghent University, Ghent, Belgium
Janssens, Sharon; Belgian Cancer Registry, Brussels, Belgium
INAMI - Institut National d'Assurance Maladie-Invalidité
Funding text :
NIHDI financed participating departments per registered case.All authors have completed the ICMJE disclosure form and declare: YL is recipient of the HERO-VBHC chair, with payments made to her institution and has unpaid leadership roles in ESTRO (Scientific Committee member and ESTRO-HERO co-chair), the Belgian College of Oncology (Board member) and in the EORTC-ESTRO E2-RADIATE project (PI); DV has research collaboration with RaySearch Laboratories and received speakers fees from BeSTRO and JASTRO and per diem payment as teacher in the ESTRO SBRT course, and reports advisory roles for the Belgian Supreme Health Council and the Medical Jury of the Belgian Federal Agency for Nuclear Control, treasurer of ESTRO and board member of \u2018Stand Up Against Cancer\u2019; ML receives a grant of the Foundation Against Cancer for proton radiotherapy in pregnancy (ProPOSE). None of the aforementioned payments or roles are in relation to the submitted work. RW receives fees as president of the College for Physicians of Radiation Oncology Centres, which are paid to her institution; SR is working for the NIHDI, HE was working for the NIHDI during the course of the CED program; SJ and NVD both work for the BCR; but none declare financial or personal interests that could have influenced the submitted work. XG, NJ, LM, VR, KS and CW reported no financial or other relationships that might impact the submitted work.
Atun, R., Jaffray, D.A., Barton, M.B., et al. Expanding global access to radiotherapy. Lancet Oncol 16 (2015), 1153–1186, 10.1016/S1470-2045(15)00222-3.
Lievens, Y., Audisio, R., Banks, I., et al. Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective. Lancet Oncol 20 (2019), e112–e123, 10.1016/S1470-2045(18)30917-3.
Borras, J.M., Corral, J., Aggarwal, A., et al. Innovation, value and reimbursement in radiation and complex surgical oncology: time to rethink. Radiother Oncol 169 (2022), 114–123, 10.1016/j.radonc.2021.08.002.
Garrison, L.P. Jr., Towse, A., Briggs, A., et al. Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health 16 (2013), 703–719, 10.1016/j.jval.2013.04.011.
Gerkens, S., Neyt, M., San Miguel, L., Vinck, I., Thiry, N., Cleemput, I., How to improve the Belgian process for Managed Entry Agreements? An analysis of the Belgian and international experience. 2017, Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE) KCE Reports 288. D/2017/10.273/41.
Torbica, A., Tarricone, R., Schreyögg, J., Drummond, M., Pushing the boundaries of evaluation, diffusion, and use of medical devices in Europe: insights from the COMED project. Health Econ 31:S1 (2022), 1–9, 10.1002/hec.4600.
Federici, C., Reckers-Droog, V., Ciani, O., et al. Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges. Eur J Health Econ 22 (2021), 1253–1273, 10.1007/s10198-021-01334-9.
Drummond, M., Federici, C., Reckers-Droog, V., et al. Coverage with evidence development for medical devices in Europe: can practice meet theory?. Health Econ 31:S1 (2022), 179–194, 10.1002/hec.4478.
Palma, D., Visser, O., Lagerwaard, F.J., Belderbos, J., Slotman, B.J., Senan, S., Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small cell lung cancer: a population-based time-trend analysis. J Clin Oncol 28 (2010), 5153–5159, 10.1200/JCO.2010.30.0731.
Ball, D., Tao Mai, G., Vinod, S., et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol 20:4 (2019), 494–503, 10.1016/S1470-2045(18)30896-9.
Lewis, S.L., Porceddu, S., Nakamura, N., et al. Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 radiation oncologists. Am J Clin Oncol 40 (2017), 418–422, 10.1097/COC.0000000000000169.
Guckenberger, M., Lievens, Y., Bouma, A.B., et al. Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol 21 (2020), e18–e28, 10.1016/S1470-2045(19)30718-1.
Palma, D.A., Olson, R., Harrow, S., et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:10185 (2019), 2051–2058, 10.1016/S0140-6736(18)32487-5.
Hulstaert, F., Mertens, A.-S., Obyn, C., et al. Innovative radiotherapy techniques: a multicentre time-driven activity-based costing study. Health technology assessment (HTA) Brussels: Belgian health care knowledge centre (KCE), 2013 KCE Reports 198C. D/2013/10.273/9.
Lievens, Y., Obyn, C., Mertens, A.-S., Van Halewyck, D., Hulstaert, F., Stereotactic body radiotherapy for lung cancer: how much does it really cost?. J Thorac Oncol 10:3 (2015), 454–461, 10.1097/JTO.0000000000000421.
National Radiotherapy Implementation Group Report. Stereotactic Body Radiotherapy. Clinical review of the evidence for SBRT. 2010, NHS England Version 1.
Lievens, Y., Guckenberger, M., Gomez, D., et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol 148 (2020), 157–166, 10.1016/j.radonc.2020.04.003.
Ost, P., Shankar, S., Brabrand, S., et al. PEACE V-salvage treatment of OligoRecurrent nodal prostate cancer metastases (STORM): acute toxicity of a randomized phase 2 trial. Eur Urol Oncol 9:23 (2023), S2588–S9311, 10.1016/j.euo.2023.09.007.
Spaas, M., Sundahl, N., Kruse, V., et al. Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS phase 2 randomized clinical trial. JAMA Oncol 9:9 (2023), 1205–1213, 10.1001/jamaoncol.2023.2132.
Guckenberger, M., Allgäuer, M., Appold, S., et al. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol 8:8 (2013), 1050–1058, 10.1097/JTO.0b013e318293dc45.
Davis, J.N., Medbery, I.I.I.C., Sharma, C., Danish, A., Mahadevan, A., The RSSearch™ Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy. Radiat Oncol J, 8, 2013, 275 http://www.ro-journal.com/content/8/1/275.
Mendez Romero, A., Schillemans, W., van Os, R., et al. The Dutch-Belgian registry of stereotactic body radiation therapy for liver metastases: clinical outcomes of 515 patients and 668 metastases. Int J Radiat Oncol Biol Phys 109:5 (2021), 1377–1386, 10.1016/j.ijrobp.2020.11.045.
Chalkidou, A., Macmillan, T., Grzeda, M.T., et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol 22 (2021), 98–106, 10.1016/S1470-2045(20)30537-4.
Iyengar, P., All, S., Berry, M.F., et al. Treatment of oligometastatic non-small cell lung cancer: an ASTRO/ESTRO clinical practice guideline. Pract Radiat Oncol 13 (2023), 393–412, 10.1016/j.prro.2023.04.004.
Nyman, J., Hallqvist, A., Lund, J.A., et al. Space – a randomized study of SBRT vs. conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol 121 (2016), 1–8, 10.1016/j.radonc.2016.08.015.
ENCR Recommendations. Treatment data recording – phase I. Version 28-06-2023. https://encr.eu/sites/default/files/Recommendations/Draft%20ENCR%20Recommendation%20treatment%20data%20recoding_20230628-for%20consultation.pdf.
Giusti, F., Martos, C., Trama, A., et al. Cancer treatment data available in European cancer registries: where are we and where are we going?. Front Oncol, 13, 2023, 1109978, 10.3389/fonc.2023.1109978.
Yalvac, B., Reulens, N., Reniers, B., Early results of a remote dosimetry audit program for lung stereotactic body radiation therapy. Phys Imaging Radiat Oncol, 29, 2024, 100544, 10.1016/j.phro.2024.100544.
Reckers-Droog, V., Federici, C., Brouwer, W., Drummond, M., Challenges with coverage with evidence development schemes for medical devices: a systematic review. Health Policy Technol 9 (2020), 146–156, 10.1016/j.hlpt.2020.02.006.
Vaandering, A., Roels, S., Yalvaç, B., et al. Favouring quality improvement initiatives: the experience of the Belgian college of radiation oncology. Precis Cancer Med, 6, 2023, 4 doi.org/10.21037/pcm-22-15.
E2-RADIatE, EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe (E2-RADIatE). NCT03818503, OligoCare cohort. https://project.eortc.org/e2-radiate/cohorts/.
Stereotactic body radiotherapy for the treatment of OPD (HALT). NCT03256981. 2023.
Stereotactic radiotherapy for oligo-progressive metastatic cancer (the STOP trial). NCT02756793. 2023.
Tsai, C.J., Yang, J.T., Shaverdian, N., et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block (CURB) oligoprogression): an open-label, randomized, controlled phase 2 study. Lancet 403:10422 (2024), 171–182, 10.1016/S0140-6736(23)01857-3.
Nevens, D., Kindts, I., Defourny, N., et al. The financial impact of SBRT for oligometastatic disease: a population-level analysis in Belgium. Radiother Oncol 145 (2020), 215–222, 10.1016/j.radonc.2020.01.024.
